| Novartis Pharma Schweiz AG - Cosentyx 300 mg / 2 ml, Injektionslösung in einer Fertigspritze |
| 65225 | | 02 | | Cosentyx 300 mg / 2 ml | | Injektionslösung in einer Fertigspritze | | L04AC10 | | Secukinumab | | 03.02.2022 | | |
|
| Composition |
| secukinumabum 300.0 mg, trehalosum dihydricum, histidinum, histidini hydrochloridum monohydricum, methioninum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 2 ml. |
| Packungsbestandteile |
| Injection solution in prefilled syringe | | | | | | | | Active Agent | Dose |
|---|
| Secukinumabum | 300mg / 2ml |
| | BAG: Active Agent | Dose |
|---|
| Secukinumabum | 300 mg |
| | | | Inactive agents |
|---|
| Histidin Hydrochloride Monohydrate | | Histidine | | Methionine | | Polysorbatum 80 | | Trehalosum Dihydricum |
| |
|
| Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 003 | | 1074.57 | 1185.10 | B | SL | Yes |
|
